Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.77 |
| ▸ | CA1 | P00915 | 3/20 | 0.65 |
| ▸ | CA2 | P00918 | 3/20 | 0.65 |
| ▸ | CA12 | O43570 | 2/20 | 0.65 |
| ▸ | CA7 | P43166 | 2/20 | 0.65 |
| ▸ | CA9 | Q16790 | 2/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.65 |
| ▸ | XDH | P47989 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30153141 | 1.00 | ERN1 (0.77) | ERN1CA1CA2CA12CA7 | |
| SCHEMBL12767865 | 0.87 | ERN1 (1.00) | ERN1CA1CA2CA12CA7 | |
| SCHEMBL1485297 | 0.86 | XDH (0.65) | ERN1CA1CA2CA12CA7 | |
| SCHEMBL17747083 | 0.85 | ALDH1A1 (0.58) | ERN1CA1CA2CA12CA7 | |
| SCHEMBL5917939 | 0.84 | CA1 (0.62) | ERN1CA1CA2CA12CA7 | |
| SCHEMBL6640776 | 0.83 | ERN1 (1.00) | ERN1CA1CA2CA12CA9 | |
| SCHEMBL9125494 | 0.83 | CA1 (0.61) | ERN1CA1CA2CA12CA7 | |
| SCHEMBL9125499 | 0.83 | CA1 (0.61) | ERN1CA1CA2CA12CA7 | |
| SCHEMBL2316486 | 0.83 | CA1 (0.61) | ERN1CA1CA2CA12CA7 | |
| SCHEMBL3507686 | 0.82 | ALDH1A1 (0.61) | ERN1CA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039135-A | Carboxyl chalcone derivative and preparation method and application thereof | 四川大学 | 2024-11-29 | — | — | CN | claimed |
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260132160-A1 | IRON REPLACEMENT TREATMENTS | THE GENERAL HOSPITAL CORP (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4727947-A1 | DYNAMIC COVALENT CHEMISTRY OF SPIROPYRANS FOR SYNTHESIS OF PHOTOSWITCHABLE PHOTOINITIATORS AND USES THEREOF | Xolo GmbH (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-20260102962-A1 | Dynamic Covalent Chemistry of Spiropyrans for Synthesis of Photoswitchable Photoinitiators and Uses Thereof, and Process for Locally Polymerizing a Starting Material by Dual Color Photopolymerization | XOLO GMBH (DE) | 2026-04-16 | — | — | US | disclosed |
| EP-4702026-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12564580-B2 | Mitochondria-targeted isoketal/isolevuglandin scavengers and uses thereof | VANDERBILT UNIVERSITY (US) | 2026-03-03 | — | — | US | disclosed |
| US-12421257-B2 | Compositions and methods for inhibiting group II intron RNA | YALE UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4604943-A2 | IRON REPLACEMENT TREATMENTS | The General Hospital Corporation (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025122979-A1 | COMPOUNDS FOR SEROTONIN RECEPTOR ACTIVATION AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | ATAI THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-5965741-A | ANTIINFLAMMATORY, ANTIPYRETIC AND ANTIDIARRHOEAL PROPERTIES | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| US-5863930-A | ATHEROSCLEROSIS TREATMENT FORMED BY REACTION OF PYRIDONES WITH BIPHENYLMETHYL HALOGEN | BAYER AKTIENGESELLSCHAFT (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5849798-A | Polyaromatic heterocyclic compounds and pharmaceutical/cosmetic compositions comprised thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-12-15 | — | — | US | disclosed |
| EP-0778821-A1 | ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF | ZENECA LIMITED (GB) | 1997-06-18 | — | — | EP | disclosed |
| US-5596006-A | ANTIHYPERTENSIVE, ANTIATHEROSCLEROTIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-01-21 | — | — | US | disclosed |
| WO-1996006822-A1 | ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF | ZENECA LIMITED (GB) | 1996-03-07 | — | — | WO | disclosed |
| WO-1995004046-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
| EP-0594019-A1 | Trisubstituted biphenyl as angiotensin II antagonistes | BAYER AG (DE) | 1994-04-27 | — | — | EP | disclosed |
| US-4272535-A | 2,4-[1H,3H,5H]-(1)-Benzopyrano-[2,3-d]-pyrimidinediones and their use as anti-allergy agents | SCHERING CORPORATION (US) | 1981-06-09 | — | — | US | disclosed |
| EP-0008277-A1 | Benzopyrano derivatives, pharmaceutical compositions containing them and processes for preparing the compounds and compositions | Technobiotic Ltd. (CH) | 1980-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421257-B2 | Compositions and methods for inhibiting group II intron RNA | NSUN2, RBM22, RNGTT | ERN1 118/4885CA1 4407/4885CA2 3530/4885 |
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | CD38, BCL9, BCL6B | ERN1 2565/4885CA1 789/4885CA2 187/4885 |
| US-12564580-B2 | Mitochondria-targeted isoketal/isolevuglandin scavengers and uses thereof | MAVS, AIFM1, TFAM | ERN1 4027/4885CA1 4850/4885CA2 2389/4885 |
| US-20260102962-A1 | Dynamic Covalent Chemistry of Spiropyrans for Synthesis of Photoswitchable Photoinitiators and Uses Thereof, and Process for Locally Polymerizing a Starting Material by Dual Color Photopolymerization | HTR3D, SPR, SRD5A1 | ERN1 3657/4885CA1 3897/4885CA2 1728/4885 |
| US-20260132160-A1 | IRON REPLACEMENT TREATMENTS | TFRC, SLC40A1, FTH1 | ERN1 2586/4885CA1 645/4885CA2 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.